BICX BioCorrx Inc

Lourdes Felix, Chief Operating Officer and Chief Financial Officer of BioCorRx Inc. Discusses the Launch of the UnCraveRxâ„¢ Virtual App in a New Interview at SmallCapVoice.com

Lourdes Felix, Chief Operating Officer and Chief Financial Officer of BioCorRx Inc. Discusses the Launch of the UnCraveRx™ Virtual App in a New Interview at SmallCapVoice.com

AUSTIN, Texas, July 29, 2019 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC QB: BICX) (the “Company”), a leader, developer and provider of advanced solutions in the treatment of addiction and related disorders, today announced that Lourdes Felix, CFO, COO and Director of BioCorRx Inc. is featured in a new audio interview at SmallCapVoice.com.

The interview can be heard at: .

Lourdes Felix called in to SmallCapVoice.com, Inc. to talk about the recent launch of the UnCraveRx™ virtual app. UnCraveRx™ is a medically assisted weight loss management program that helps to reduce food cravings combined with on-demand virtual lifestyle support, fitness and nutrition. The UnCraveRx™ App is available now. It is available online or through the Android or iOS app stores.

"We are looking forward to the full launch of the UnCraveRx™ Weight Loss Management Program in the fall of this year. We estimate that the program will be a key growth revenue driver for BioCorRx and remain focused on building shareholder value," stated Felix.  "Once again, we are thankful for the opportunity to share our story with our shareholders and the SmallCapVoice.com listening audience.”

About BioCorRx

BioCorRx Inc. (BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. The BioCorRx® Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance use; please visit for more information on the BioCorRx Recovery Program. The UnCraveRx™ Weight Loss Program is also a medication assisted program; please visit for more information on UnCraveRx™. The Company also conducts R&D under its controlled subsidiary, BioCorRx Pharmaceuticals. For more information on BICX and product pipeline, please visit

About SmallCapVoice.com Inc.

SmallCapVoice.com Inc. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks in which they are interested. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and its services, please visit

BioCorRx Inc.



714-462-4880



Investor Relations:

Crescendo Communications, LLC

(212) 671-1020 x304

SmallCapVoice.com Contact

Stuart T. Smith

512-267-2430

EN
29/07/2019

Underlying

BICXBioCorrx Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCorrx Inc

 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Reports Business Update for the Second Quarter of 2024

BioCorRx Reports Business Update for the Second Quarter of 2024 ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2024, and reported on recent corporate developments. Additionally, BioCorRx Inc. announces the expansion of its intellectual property portfolio with a new international patent awarded from Israel for the treatment of weight loss. This patent covers the use of a subcut...

August 15, 2024 1 EN
 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to...

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO). The USPTO has issued U.S. Patent No. 11,793,801 entitled, “Treatment of Pain and Neurologi...

April 3, 2024 1 EN
 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Reports Business Update for 2023

BioCorRx Reports Business Update for 2023 ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid ...

April 2, 2024 1 EN
 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 ...

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year grant for approximately $11 million from the National Institute on Drug Abuse (NIDA), part of the National Institut...

February 28, 2024 1 EN
 PRESS RELEASE
Free
BICX BIOCORRX INC

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarne...

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the first six-month, subcutaneous implant approved in the United States, Canada, a...

February 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch